SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    WHO Technical Report Series No. 9m. The burden of musculoskeletal conditions at the start of the new millenium. Geneva: World Health Organization; 2003.
  • 2
    Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984; 27: 86472.
  • 3
    Albers JM, Kuper HH, van Riel PL, Prevoo ML, van 't Hof MA, van Gestel AM, et al. Socio-economic consequences of rheumatoid arthritis in the first years of the disease. Rheumatology (Oxford) 1999; 38: 42330.
  • 4
    Sokka T, Kautiainen H, Mottonen T, Hannonen P. Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol 1999; 26: 16815.
  • 5
    Young A, Dixey J, Cox N, Davies P, Devlin J, Emery P, et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). Rheumatology (Oxford) 2000; 39: 60311.
  • 6
    Doeglas D, Suurmeijer T, Krol B, Sanderman R, van Leeuwen M, van Rijswijk M. Work disability in early rheumatoid arthritis. Ann Rheum Dis 1995; 54: 45560.
  • 7
    Katz PP. The impact of rheumatoid arthritis on life activities. Arthritis Care Res 1995; 8: 2728.
  • 8
    Reisine S, Fifield J, Winkelman DK. Employment patterns and their effect on health outcomes among women with rheumatoid arthritis followed for 7 years. J Rheumatol 1998; 25: 190816.
  • 9
    Stamm TA, Wright J, Machold KP, Sadlo G, Smolen JS. Occupational balance of women with rheumatoid arthritis: a qualitative study. Musculoskelet Care 2004; 2: 10112.
  • 10
    Stucki G, Ewert T, Cieza A. Value and application of the ICF in rehabilitation medicine. Disabil Rehabil 2002; 24: 9328.
  • 11
    Boers M, Tugwell P, Felson DT, van Riel PL, Kirwan JR, Edmonds JP, et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying anti-rheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl 1994; 41: 869.
  • 12
    World Health Organization. ICIDH: International Classification of Impairments, Disabilities and Handicaps. Geneva: WHO; 1980.
  • 13
    Nagi SZ. A study in the evaluation of disability and rehabilitation potential: concepts, methods, and procedures. Am J Public Health Nations Health 1964; 54: 156879.
  • 14
    World Health Organization. ICF: International Classification of Functioning, Disability and Health. Geneva: World Health Organization; 2001.
  • 15
    Stucki G, Cieza A, Geyh S, Battistella L, Lloyd J, Symmons D, et al. ICF Core Sets for rheumatoid arthritis. J Rehabil Med 2004; 44 Suppl: 8793.
  • 16
    Hewlett S, Smith AP, Kirwan JR. Values for function in rheumatoid arthritis: patients, professionals, and public. Ann Rheum Dis 2001; 60: 92833.
  • 17
    Hewlett SA. Patients and clinicians have different perspectives on outcomes in arthritis. J Rheumatol 2003; 30: 8779.
  • 18
    Kirwan J, Heiberg T, Hewlett S, Hughes R, Kvien T, Ahlmen M, et al. Outcomes from the Patient Perspective Workshop at OMERACT 6. J Rheumatol 2003; 30: 86872.
  • 19
    Kvale S. Interviews: an introduction to qualitative research interviewing. Thousand Oaks (CA): Sage; 1996.
  • 20
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 21
    Jones K. The turn to a narrative knowing of persons: one method explored. Nursing Times Research; 2002. URL: www.angelfire.com/zine/kipworld/The_turn.pdf.
  • 22
    Depoy E, Gitlin LN. Introduction to research. St. Louis: Mosby; 1998.
  • 23
    Karlsson G. Psychological qualitative research from a phenomenological perspective. Stockholm: Almquist & Wiskell International; 1995.
  • 24
    Cieza A, Brockow T, Ewert T, Amman E, Kollerits B, Chatterji S, et al. Linking health-status measurements to the International Classification of Functioning, Disability and Health. J Rehabil Med 2002; 34: 20510.
  • 25
    Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960; 20: 3746.
  • 26
    Vierkant RA. A SAS macro for calculating bootstrapped confidence intervals about a kappa coefficient. SAS Users Group International Online Proceedings; 2004 July 23. URL: http://www2.sas.com/proceedings/sugi22/stats/paper295.pdf.
  • 27
    Carr A, Hewlett S, Hughes R, Mitchell H, Ryan S, Carr M, et al. Rheumatology outcomes: the patient's perspective. J Rheumatol 2003; 30: 8803.
  • 28
    Axelrod L. Glucocorticoids. In: KellyWN, HarrisED, RuddyS, SledgeGB, editors. Textbook of rheumatology. Philadelphia: W. B. Saunders; 1993. p. 77996.
  • 29
    Brooks PM. Drug modification of inflammation: non-steroidal anti-inflammatory drugs. In: MaddisonPJ, IsenbergDA, WooP, GlassDN, editors. Oxford textbook of rheumatology. Oxford: Oxford University Press; 1993. p. 3238.
  • 30
    Deman AM, Brooks PM. Antirheumatic therapy. In: MaddisonPJ, IsenbergDA, WooP, GlassDN, editors. Oxford textbook of rheumatology. Oxford: Oxford University Press; 1993. p. 32949.
  • 31
    Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004; 43: 90614.